Background: The standard-of-care regimen for chronic hepatitis C virus (HCV) infection in Korea, pegylated-interferon-alpha plus ribavirin, is poorly tolerated. Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection. Methods: This single-arm, phase IIIb study (NCT02021656) investigated the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 HCV with or without compensated cirrhosis. Results: The proportion of patients with sustained virologic response 12 weeks after treatment discontinuation (SVR12) was 99 % (92/93), with rates of 100 % (46/46) and 98 % (46/47) in treatment-naïve and treatment-experienced patients, respectively. There were no on-treatment failures. One patient relapsed after the end of treatment. The most common treatment-emergent adverse events were headache (8 %, 7/93) and fatigue (6 %, 6/93). There were no grade 3 or 4 adverse events, seven grade 3 laboratory abnormalities, and one premature discontinuation of study treatment (due to nonserious mouth ulceration). None of the three reported serious adverse events were related to treatment. Conclusions: These data suggest that 12 weeks of ledipasvir/sofosbuvir is effective and well tolerated in treatment-naïve and treatment-experienced Korean patients with chronic genotype 1 HCV infection.
Bibliographical noteFunding Information:
Young-Suk Lim has served as an advisor for Bayer Healthcare, Bristol-Myers Squibb, and Gilead Sciences, and has received research funding from Bayer Healthcare, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Sang Hoon Ahn has served as an advisor and lecturer for Bristol-Myers Squibb, Gilead Sciences, F. Hoffmann-La Roche, Merck, Janssen, AbbVie, Novartis, Boeringher Ingelheim, and AVIVAX, and has received unrestricted grants from Bristol-Myers Squibb, Gilead Sciences, and F. Hoffmann-La Roche for investigator-initiated trials. Seung Woon Paik has received research funding from Bristol-Myers Squibb, Gilead Sciences, F. Hoffmann-La Roche, Merck, Janssen, and AbbVie. Hyung Joon Yim has received research funds from Handok Pharmacuetical Company and Gilead Sciences. Yoon Jun Kim has served as a speaker and advisory board member for Gilead Sciences, Bayer Healthcare, AbbVie, Novartis, and F. Hoffman-La Roche and has also received research funding from Gilead Sciences, Bristol-Myers Squibb, and F. Hoffman-La Roche. Kwan-Soo Byun has served as an advisory board member for Gilead Sciences and has received research funding from Gilead Sciences, Bristol-Myers Squibb, and Medigen Biotechnology Corporation. Jenny C. Yang, Hongmei Mo, Kimberly L. Garrison, Bing Gao, Steven J. Knox, and Phillip S. Pang are employees of and own stocks and shares in Gilead Sciences, Inc. Kwan Sik Lee, Youn-Jae Lee, Sook-Hyang Jeong, Ju-Hyun Kim, Seung Kew Yoon, Won Young Tak, Sang-Young Han, Young Seok Kim, Jeong Heo, and Kwang-Hyub Han have nothing to declare.
© 2016, Asian Pacific Association for the Study of the Liver.
All Science Journal Classification (ASJC) codes